CA2148617C - System for dispensing pharmaceutically active compounds - Google Patents

System for dispensing pharmaceutically active compounds Download PDF

Info

Publication number
CA2148617C
CA2148617C CA002148617A CA2148617A CA2148617C CA 2148617 C CA2148617 C CA 2148617C CA 002148617 A CA002148617 A CA 002148617A CA 2148617 A CA2148617 A CA 2148617A CA 2148617 C CA2148617 C CA 2148617C
Authority
CA
Canada
Prior art keywords
pharmaceutically active
active compound
metered dose
inhaler
microns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002148617A
Other languages
French (fr)
Other versions
CA2148617A1 (en
Inventor
Jan Anders Roland Andersson
Hans Ake Ingemar Jagfeldt
Eva Ann-Christin Trofast
Kjell Ingvar Leopold Wetterlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra AB filed Critical Astra AB
Publication of CA2148617A1 publication Critical patent/CA2148617A1/en
Application granted granted Critical
Publication of CA2148617C publication Critical patent/CA2148617C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Abstract

The use of an inhaler having the capacity to dispense a high proportion of pharmaceutical substance in inhalable powder particles of up to 10 microns in diameter permits the use of a lower metered dose of the pharmaceutical substance as compared with the metered dose required when a conventional MDI is used.

Description

ffi.f'~ .
1~0 94/132?1 PC~'1SE93/01053 ~~~~~~~ 1 SYSTEM FOR DISPENSINCg PI-IARMACEUTICALLY
ACTIVIE COMPOUNDS
This invention relates to a system comprising a dry powder inhaler and a ' S pharmaceutical substance, for dispensing clinically effective doses of pharmaceutically active compounds such as (~-2 agonists, corticosteroids, anti-cho~inergic and other pharmaceutically active compounds for local or systemic treatment of diseases which have the p~tential for treatment with inhalable drugs.
~ackQround of the Invention Inhalable drugs are commonly used in the treatment of disease of the airways and lungs such as rhinitis; asthma, and chronic bronchitis. As examples of such drugs may bw mentioned X32-adrenoreceptor agonists such as salbutamol~ terbutaline, rimiterol, fenoterol, reproterol; adrenalirse, pirbuterol, isoprenaline;
orciprenaline, ' bitolteroI, salmeterol, fbrmoterol; clenbuterol procaterol, broxaterol;
picumeterol, TA-2005, mabuterol and the like, and their pharmac~logically acceptable esters and salts; anticholinergic bronchodilators such as ipratropium bromide and the like;
glucocorsticosteroids such as betamethasone; flutieasone, budesonide;
tipredane, 2p deuamethasone; betarnethasone; fluocinolone, triamcinolone; mometasone, D-and the like; and their pharrn~cologic~lly acceptable esters and salts; anti-allergic drugs such as sodium cromaglycate and nedocromi.l sodium; expecaorants;
mucolytics; andhistarnines; cyclooxygenas inhibitors; leukotrie~e synthesis inhibitors; leakotriene antagonists, P'LA2 inhibitors, PAF antagonists and . 2~ prnphylaCtics;of asthma:. In addition to these, a wide range of systerizically'acting drugs may be administered vaa the respiratory tract. As examples of these may be mentioned antiarrhythmic drugs; tranquilisers, cardiac glycosides; hormones, anti-hypertensive drugs; antidiabetic- antiparasitic- and anticancer- drugs, sedatives and aha.lgesic drugs, ~ntit~iotics, antirheumatic drugs; immunotherapies, a.ntifungal and ~~ ~~yPotension drugs, vaccines, antiviral drugs, proteins, peptides, vitamins and n , ,, ., , : . . .<:...: . .... .., :. ,,.. > ...., . . -:. .. ,.,.: , ... , ; . ~ .
S .::....~. ...;:-.. .~!:.: ..~:.. .:..~~:.,~ .,::-...,.. ~...,. " :"; .
;!:.:.. ...:,..,.;.. .,. ~........,, . <...a...:... .~.~;.~ v ....',.,.,..
':.:~~. :.~."~., ..:..~,:,,.. ,.,..... .. . .
v i . , . . ,. . .." .~:..:. .',:u .: ,:.. .;..,; ., , ..:.. , ~ ,,..: , ....:.
..:'-: ',: ' . ~. -. -,~,.;:, ;...,..: ~.':'~.. .. :: -.. ... : '. , .
..r,:". ~ . . .:, .. . :.,.. . . ... . ,. .. . , .: . ..: . .. .. . . ...
~,... ... . .. . , .. . , .. ..:

::_,: l W~ 94!13271 PCT/S193/01053 ' '.
others, such as cell surface receptor blockers.
Inhalable drugs are commonly administered using a metered dose inhaler (TViDI) or using a dry powder inhaler (DPI). The lVifDI, in which the drug is dissolved or suspended in a liquid propellant mixture (sometimes including small amounts of a volatile organic or inorganic solvent) is hitherto the more widely used device and functions by dispensing drug upon activation, by the patient, of a dosage in coordination with inhalation. The DI?I, in which the drug is present as a dry powder, frequently together with a carrier, dispenses drug by means df the particle cloud generated by the airflow obtained upon patient inhalation.
The aim of both the IvIDI and the DPI is' to deposit a clinically effective amount of . active compound in the lungs. Ay "clinically effective amount of active compound" is meant that amount of active compound which is required in order to effect a response.
If handled correctly, 1VIDI's and many DPI's deliver pharmaceuticals to the active site in approximately the same efficaency; however the amount of active substance which reaches the lungs in each case is only in the region of 10% bf he amount in the metered dose. In' order therefore to ensure a clinically effective amount of active compound in the lungs, this metered dose musty necessarily contain a much larger than clinically effective amount of active compound. 'lChe active compeund which does net reach the lungs is lost mainly in the apparatttas and ga~trointescinal tzact: This is disadvantageous, since loss of active substance in the apparatus is ,. ~2~ costly and may reduce efficiency further; by far example chgging'the mduthpiece er inhalatsotr channel. ll~ore significant for the patient, loss in the gastrointestinal tract can trigger or accentuate side effects, which are as5o~iated with the use of any effective pharmaceutical. In the case of bronchodilators for example, possible side effects carnznomly include tremor end increased heart rate, and irritati~n of the ~0 h~ei.~.eactive airways of many sufferers of airway disease.

W~ 94/13271 2 ~. 4 ~ ~ ~. '~ PCTlSE93101053 There has come onto the markee new types of dry powder inhalers which are able to facilitate the dispensation of pharmaceutical substance in which a high proportion of the dispensed particles are of diameter up to 10 microns. It is conventional practice that powders are prepared prior to loading into an inhaler, into primary particles with as many as possible of these particles having a diameter of up to 10 microns. However the nature of such fine powder causes larger agglomerates c~ be formed, in high proportion, and only a small percentage of the particles which are actually dispensed from the inhaler exist in the primary particle diameter range.
The fast of the above said new dry powder inhalers to come onto the market was a unique, multi-dose breath-actuated dry powder inhaler as is described in :y European Patents numbers 0 237 507 and 69 715 and known by the trade mark "TURBLJHALER". It features deagglomeration means which function by dismpting the particle agglomerates to give a higher proportion of particles in the primary particle diameter range ofvup to 10 microns. It has generally been thought (see for example Eogaard et al in "Pharmatherapeutica", X01.5; hdo.6, 1989) that this new inhaler has efficiency only comparable to a prior art dry powder inhaler (and therefore alsa to an IvIDI). Recommended dosages have therefore been of the same order as those recommended with are IViIE~I.
The Invention It is an aim of the present invention to provide for lower dispensing doses of ?~5 pharrr:aceutical'substance'to be used; with'the result that wastage arid side-effects are minimalised.
~?Ve have now most surlarisin~ly found that the use of an inhaler such as the breath-actuat~d dry p~wder inhaler of the ype described in EP 0 237 S07 and EP 69,715 and known by the trademark TIJ1ZBLTHALEA, permits the use of a lower dose than rp.~~y , , ,.v: ~: r : ; >;:,_ ,. , ~:~ ~ . . ' ';:. , .; ,.r::... ., ,., c: ,. <.:...
...,. .. , ..:. :. ..
fiy~1~~ ~ .7. .. ~..l .' ~.1.
.w..~~...f'. .:. ". ... . , , ,. '..~~ .. ....n: ...'..:r' '.: .'. ,'.: ~
~.~.... ,. ..' ',.: .': '..:.s:: 's . ~. .~y.~'... :W'.'',. . ..,.,.:~ ' J
.f~.~....,...\ .,......lo,. ...'.... n . n r. . "..:~..... ,.,. . . ..
,......;..... ... .; ., ..... .. v .. .. ...,.., . . ,. . .. ..... .. . '.

a MDI, in the dispensation of a clinically effective dose of active compound for administration by inhalation and that consequently, the use of such an inhaler as above can reduce the side-effects associated with drug administration.
After the TURBUHALER inhaler have come other dry powder inhalers which are also able to dispense a high proportion of pharmaceutically active compound in particles of up to 10 microns. As an example of these may be mentioned the breath-actuated dry powder inhaler which is described in patent applications WO 92/04069 and WO
93/17728, and which is known by the trademark ~~MONOHALER".
Such inhalers are also able to be used in the present invention.
According to this invention therefore, there is provided a system comprising a dry powder inhaler and a metered dose of an inhalable pharmaceutically active compound in powder form, for dispensing a clinically effective dose of the inhalable pharmaceutically active compound, comprising a dry powder inhaler having the capacity to dispense at least 40% of the metered dose of pharmaceutically active compound in inhalable particles of up to 10 microns in diameter, and the said metered dose of pharmaceutically active compound comprising primary particles of which at least 80o have a diameter of up to 10 microns, which metered dose is in an amount which is not more than 70% by weight of the metered dose which when used with a MDI is equally clinically effective.
According to one aspect of the present invention, there is provided a system comprising a dry powder inhaler and metered dose of at least one inhalable pharmaceutically 4a active compound selected from terbutaline, salbutamol, formoterol, budesonide, salts thereof and hydrates thereof, in powder form, for dispensing a clinically effective dose of the inhalable pharmaceutically active compound, wherein (i) the dry powder inhaler is selected from Turbuhaler ~ and "Monohaler"; (ii) the said metered dose of pharmaceutically active compound comprises agglomerates of primary particles wherein at least 800 of the primary particles have a diameter of up to 10 microns capable of being deagglomerated in the inhaler; and (iii) which metered dose is in an amount which is not more than 70o by weight of the metered dose which when used in an MDI is equally clinically effective.
Preferably the dry powder inhaler used in the present invention is a breath-actuated dry powder inhaler.
Preferably at least 90% of the primary particles have a diameter of up to 10 microns.
The advantage of a lower metered dose in accordance with the present invention is ~,y~ 9d/13271 PCT/SE93/01053 reflected in greater lung deposition if equal doses of pharmaceutically active compound are used in a dry powder inhaler such as for use in the present invention and in a conventional MDI.
' S 1'~r~ferably the metered dose of pharmaceutically active compound for use in the present invention is not more than 50%, more preferably not more than 40%, of the metered dose which when used with an MIDI is equally clinically effective.
Preferably at least 50% of particles which are dispensed in accordance with the present invention have a diameter of up xo S microns when dispensed.
FreferabIy, the dry powder inhaler of the present invention i~
one of the breath-actuated dry powder inhalers referred to hereinabove which are known by the n trademarks TURBUH~1LE~. and M~N(3HALElZ.

The pharmaceutically active compound of the present invention may if desired be contained in a pharmaceutical formulaiion containing commonly used additives such as diluents and/or carrier substances which are generally non-toxic and chemically inert to the pharmaceutically active compound. For example a carbohydrate such as lactose; glucose, fructose, ~alaGtose, trehalose, sucrose maltose zylitol, myoir~~sitol, dextrane, starch and the like or a hydrate thereof;
and especially lactosd; rhannitol or myoinositol, or an amino acid such as alanine, Maine and the like, or any additive which wiJ1 irupart a desired property such as taste or a physiochemical or ph~rrmaceutical property, may be employed.
F-iowever, it is stressed that the pharmaceutical active compound for use in the' pre~iit invention requires no additive and may advantageously be used in its pure form.

Therefore tho pharmaceutically active compound of the present invention is conta.iz2ed in a pharmaceutical fornnulation in powder form containing the pharmaceutically active compound:
alone or in combination with appropriate ;, .;.:1 WO 94/13271 ' PC7CISE93/01~53 214~6~.~
additives, and may be used as the powder or be contained in a capsule or loaded on an elongate carrier such as a tape, web or belt wherein it is used in conjuction with an appropriate inhaler which dispenses the desired powder particles.
An inhaler will only dispense the desired powder particles if the pharmaceutically active compound itself is in a form suitable for yielding particles in the desired size range. 'Therefore it is essential that the pharmaceutically active compound for use in the present invention is in the form of a povrder comprising particles of which at Least 80%, and preferably at least 90%, are of diameter less than 10 microns, or in the form of agglomerates of such particles. Such powder may be obtained in conventional manner, if necessary.
,, Any inhalable pharmaceutically active compound which has adequate physicochemical pharmaceutical and powder characteristics, as reco~mised in the art and including for example suitable particle size, agglomerability, deagglomerabiiity, flowability, melting point, crystatlinity and hygroscopicity is suitable for use in the present invention. As examples'of thrdse may be mentioned X32-adrenoreceptor agonists such as salbutamol, terbutaline, rirruterol, fenaterol, reproterol, adrenaline, pirbuterol, isoprenaline, orciprenaline, bitolterol, salmeterol, formoterol, clenbuterol,procaterol, broxaterol; picumeterol, TA-~OIyS, mabuterol and the like.
arid theix pharmacologically acceptable esters and salts; anticholinergic bronchodilators such as ipratr~pium bromide and the like;
glucocorsticosteroids such as betamethasone, flutieasone; budesonide, tipredane, dexamethasone, betarrtethasorre,' fluocinolone, triamcinolone,. mometasone, p-5519 and the like, and 'z5 ' ' their pharrn~cologically acceptable esters and salts; anti=allergic drubs sucH as soriium cromdglycate and nedocr~mil sodium; expectorants; rrucolytics;
antihistamines; cycIooxygenas inhibitors; leukotxiene synthesis inhibitors;
le~~~ene antagonists PL;A2 inhibitors, PAF antagonists and prophylactics of asthma; and antiarrhythmie'drugs, tranquilisers, cardiac glycosides, hormones, anti-hypertensive drugs; antidiabetic- antiparasitic- and anticancer- drugs, sedatives and W(? 94/I3271 PCT/SE93/DIU53 analgesic drugs, antibiotics, antirheumatic drugs, immunotherapies, antifungal and antihypotension drugs, vaccines, antiviral drugs, proteins, peptides, vitamins and others, such as cell surface receptor blockers.
a '1'he present invention is especially useful when the pharmaceutically active compound is a ~3-2 agonist such as terbutaline, salbutannol, formoterol, budesonide or theia salts or hydrates or a mixture of any of the sand ~3-2 agonists or their salts or hydrates with'carbohydrat~; especially lactose, mannitol or myoinositol, or any of the following mixtures: ipratropium bromide and lactose, formoterol and budesonide, ipratropium bromide and budesonide, terbutaline and sodium cromoglycate; terbutaline and bude~onide.
Since drugs targetted at the same disease are commonly not equipotent; the dispensing doss and ~f courso the clinically effective amount of active compound referred to will be different for different drugs. For example, the (3-2 agonist salbutamal is generally accepted as being snore potent than the ~3-2 agonist terbutalirae sulphate, 0.l mg of vsalbutamol generally being regarded as equipotent to Q.25 mg of terbutaline sulphate. In any assessment of efficiency therefore, ~uipotent doses of phaamaceutically active compounds should bo directly compared. Recommended lViDl doses of many common inhatable drugs are well known. I~ accordance mth the present mventzon; these recommended doses can be i FetlUGed. For example; the metered dose of salbutamol, budesonide and erbutaline gay ~ reduced.. by a factor of two in accordance with the present invention.
;25 In the dispensing of a clinically effective dose; morn' than oiie metered 'dole may be r~uued, ,depending on the patient; disease, ~d drug profile.
The pz~sent invention also provides the use of a dry powder inhaler having the capacity to dispetsse at least 4Q % of the metered dose of phaamaceutically active compound in inhalable particles of up to 10 microns in diameter, the metered dose W0 94!13271 PCTlSE93l01053 of pharmaceutically active compound in powder form comprising primary particles of which at Ieast 80% have a diameter of up to 10 microns, which metered dose is not more than 70% (by weight), and preferably not more than 50% by weight, of the metered dose which when used in a ~iDI is equally clinically effective, in the administzation to a patient of a clinically effective amount of an inhalable drug.
Further the present invention provides an improved method of administering a clinically effective amount of a pharmaceutically active compound, comprising using a dry powder inhaler havirDg the capacity to dispense at least 40 % o~
the metered dose of pharmaceutically active compound in inhalable particles of up to 10 microns in diameter; and a metered dose of pharmaceutically active compound in powder form comprising primary particles of which at Least g0% have a diameter of up to 10 ryicrons, which metered dose is not more than 70% (by weight), and preferably not more than 50% by dveight, of the metered dose which 1~ when used in a INLDI is equally clinically effective.
'~ ~''et fuz~her this invention provides a method for floe treatment of diseases which arP treatable with inhalable dregs, comprising administering to a patient suffering therefrom a clinically effective amount of'pharmaeeutically active compound, using a dry powder inhaler having the capacity to dispense at least 40 % o~ the metered ~' dose of pharmaceutically active compound in inhalable particles of up to 10 ;microns in diameter, and a metered dose of pharmaceutically active compound in articles of which at least ~0% have a diameter powder form comprising primary p of up to 10 microns, whici~ metered dose is not more than 70% (by weight), and preferably not more than 50% by weight, of the metered dose., ~,hich~ when used in a Ie~IDI is equally clinically effective.
The invention will now be illustrated by Examples which are intended to illustrate but not to limit the scope of the invention.
..; 30 .. ,... . . . . "_. . . .. -:: ,.: .: .. .; " .. ,... - .:~: . .~.: . .:;...;-: -.., w, _-.
.:. . . ,... . . . ... ; : ,,., .. . . : .. . ... , . .. . .. ., .. .... .
..., . . . ...:.. ., . , ., 2'31 _ ~ PCT/SE93/01~53 E~camples Particle size analysis: TURBUFIALER v MDI
In vitro studies have shpwn that the delivery of budesanide by Turbuhaler at inspiratory flows of 60 litres/minute Leads to a greater proportion c~f fine particles than the delivery by art MDI. The measurements were performed with a four-stage (>I3, ?-13-, 4-'7 find 1-4 microns) cascade impactor, which operates at a flow rate of 60 litres/minute: Five separate of each device were tested. The results are i0 presented in Figure 1:
E~amt~le 1 - Budesonide: TURBUHALER v MDI

In order to determine the absolute systemic availability and the amount deposited and absarb~ed in the lung of budesonide after inhalation via Turbuhaler and via an MDI, 24 healthy subjects ~rere given budesonide L trig as five inhalations of 200 microns via 'I'urbuhaler or MDI, and l.5 mg intravenously, on separate study days.

Budesonide levels were determined' in plasma by a LC-MS method. The am~unt of budesonide absorbed in the lung dyes calculated on the assumptioia of an availability of swallowed budesonide of 13%. Furthermore; absorption i~
the lung was caleulat~d in 13 of the subjects after mhalatic~n with concoamnant oral dosing of charcoal to prevent absorption of budesanide from the gastrointestinal tract.

There was good conformity between the twa modes of calculation.

, .~ ~ w , , ,, From Turbuhaler; the absolute systemic availability of budesonide,~
as a geometric i the MDI this fi a was 28%. AMAX and TMAX were 3.6 mean, was 3S%. Fo , ~' nmol/1 and 0.3 hours with Turbuhaler, and 2.3 nmol/1 and 0.5 hours with the MDI.

The amount of budesonide deposited and absorbed in the lung as a geometric mean was 32% (16%-59%) for Turbuhaler and l5% (3%-47%) for the MDI. This shows a lung d~pvsition of budesanide froth Turbuhaler which is less variable and twice ,.;. ..=...., :~. ; _, ;.. : . ;...: ,;. ;,...: . e: ,.< . ..;. ;,.,.
. .. ... . ... .: . . . . . ... ,,; ,..... ..__.. .;
. , , , . _ : : . .. ,, . .. ,... . , , :,. ., ,...: . .. ,.:.. ... . .
.
,.. .
.

~~.~s~~ 1~
_.._ that from an 1~I~I, and demonstrates that a lower metered dosage may be used when Turbuhaler is employed.
l;xam~le 2 - Terbutaline: TI7~~'(rEIALEI~ v MIDI
Eight healthy volunteers were administered terbutaline sulphate tagged with (99m)Tc from Turbuhaler or lVgI?I on two separate days at least 4.g hours apart in randomised cross-over fashion. In order to deposit approximately lOIviPq (99m)Tc in the body on each study day, four doses of terbutaline sulphate (total 1 mg) were given by I~II~I and two doses of terbutaline sulphate (total 1 mg).were given by Turbuhaler, Administration of radioactive aerosol was performed with the inhaler connected in series with a Vitalograph lI~I~I-compace spirometer (Vitalograph Ltd, UIC) modif ed for measuring inhalation flows. An average inhalation floe~r rate of 30 1/min was aimed at for the ICI and a peak inhalation flow rate of ~0 1/min was aimed at for Teybuhaler. These flow rates are believed to ~ optimal with respect to drug delivery to the lungs for the two devices. After inhalation the volunteers were instz°ucted to hold their breath for 10 seconds before exhaling through an exhalation filter (Pall l_)Itipor, LTI~) that retains terbutaline inhaled into, but not deposited in, the lungs: 'The MIDI was actuated by an investigator during the course of inhala;tiona Lung function tests were performed'before and after izahalation of the labelDed terbutaline to ensure that no deterioration in lung function had occured. Imxnedixtely after inhalation of a study drug, a posterior view of the lungs, ah anterior view of the lungs and a lateral view of the orr~pharynx were a taken by gamma camera (General Electric ll~axicamera) connected on line to a IVodeci~st computer system. Gamma radiation from the mouthpiece and exhalation filter was alsn ra~eas~ed. All images were stored on magnetic tape for subsequent data analysis: From 'these measurements the fraction of the anetered dose into the lungs could be determined.; The me surements, when adjusted to take account of i an observed mismatch between the distributions of unlabelled dnig, labelled drug ~0 and radiolabel,for 'Turbuhaler, gave a mean value of 29.3% for total lung . , . . . . " r . . . . . , . . . ~. . . : .
.,.:: .:. ; . .:... _ ... .... _..,.. : . . ,. . ..... . ,: . :. .;,... .
:.::.;..
..:: ... , ... . ,. . . . .. , : ; :. . ., . .. ., ~ . ... ,. :... . : .. .
... . : , PCTI~E93I01053 11' .. .' ' ' deposition (Turbuhaler), compared with 16.7% for a Iv~I. These figures indicate the possiblity of using a lower metered dose when Turbuhaler is employed.
Example 3 - Salbutamol: TURBLII-IAI,Eit v MDI
The relative e~cacy of cumulative doses (1~ micrograms up to 1604 micrograms) ;, ~~ of in a MDI was com aced of salbutamol m Turbuhaler and Ventolin (salbutam ) p in 12 patients wide reversible obstructive airway disease. The results are indicated in Figures 2 and 3 and show that albutamol delivery is more e~cient from Turbuhaler. 'I'heref~re the metered dose can be lower for the same clinical effect.
Example 3A - Salbutamol: Particle Distribution The absolute pulmonary deposition of salbutamol inhaled via Turbuhaler and a MDI was investigated. Salbutamol was mixed vsdth lactose in order to achieve' lower dosing without affecting the dosing accuracy. Individual data from 7 healthy volunteers indicated a difference in d~posicion favouring Turbuhaler. The results ~e presented in 1~igure 4.
Example 4 - lBudesonid~: MI~JNC~HALER
Particle size distribution frora9 Monohaler lass been found to b~ eotnparable with Turbuhaller particle size distribution: This would indicate that Ivlonohaler also has high efficiency at least compared with a l~iDI, and the advantage of lower dosing ,, ; , requireanents c~ be expected, ,

Claims (6)

CLAIMS:
1. A system comprising a dry powder inhaler and metered dose of at least one inhalable pharmaceutically active compound selected from terbutaline, salbutamol, formoterol, budesonide, salts thereof and hydrates thereof, in powder form, for dispensing a clinically effective dose of the inhalable pharmaceutically active compound, wherein (i) the dry powder inhaler is selected from Turbuhaler ® and "Monohaler"; (ii) the said metered dose of pharmaceutically active compound comprises agglomerates of primary particles wherein at least 80% of the primary particles have a diameter of up to 10 microns capable of being deagglomerated in the inhaler; and (iii) which metered dose is in an amount which is not more than 70% by weight of the metered dose which when used in an MDI is equally clinically effective.
2. A system according to claim 1, in which at least 90% of said primary particles have a diameter of up to 10 microns.
3. A system according to claim 1 or 2, in which the metered dose of the pharmaceutically active compound is not more than 50% of the metered dose which when used with an MDI is equally effective.
4. A system according to any one of claims 1 to 3, in which the pharmaceutically active compound comprises a hydrate of terbutaline, salbutamol, formoterol, or budesonide, with a carbohydrate.
5. A system according to claim 4, in which the carbohydrate is lactose, mannitol or myoinositol.
6. Use of the system according to any one of claims 1 to 5, in the treatment of a disease responsive to treatment with at least one of the inhalable pharmaceutically active compounds defined in claim 1.
CA002148617A 1992-12-11 1993-12-07 System for dispensing pharmaceutically active compounds Expired - Fee Related CA2148617C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9203743A SE9203743D0 (en) 1992-12-11 1992-12-11 EFFICIENT USE
SE9203743-1 1992-12-11
PCT/SE1993/001053 WO1994013271A1 (en) 1992-12-11 1993-12-07 System for dispensing pharmaceutically active compounds

Publications (2)

Publication Number Publication Date
CA2148617A1 CA2148617A1 (en) 1994-06-23
CA2148617C true CA2148617C (en) 2003-12-30

Family

ID=20388104

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002148617A Expired - Fee Related CA2148617C (en) 1992-12-11 1993-12-07 System for dispensing pharmaceutically active compounds

Country Status (8)

Country Link
US (3) US5642728A (en)
EP (1) EP0673244A1 (en)
JP (1) JPH08504438A (en)
AU (1) AU5663494A (en)
CA (1) CA2148617C (en)
IS (1) IS4102A (en)
SE (1) SE9203743D0 (en)
WO (1) WO1994013271A1 (en)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6250300B1 (en) 1992-12-11 2001-06-26 Ab Astra System for dispensing pharmaceutically active compounds
SE9203743D0 (en) * 1992-12-11 1992-12-11 Astra Ab EFFICIENT USE
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
AUPM411494A0 (en) * 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
MX9706449A (en) * 1995-02-28 1997-11-29 Hoechst Marion Roussel Inc Pharmaceutical composition for piperidinoalkanol compounds.
US5669973A (en) * 1995-06-06 1997-09-23 David Sarnoff Research Center, Inc. Apparatus for electrostatically depositing and retaining materials upon a substrate
US5714007A (en) * 1995-06-06 1998-02-03 David Sarnoff Research Center, Inc. Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
GB9515182D0 (en) † 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5642727A (en) * 1995-07-25 1997-07-01 David Sarnoff Research Center, Inc. Inhaler apparatus using a tribo-electric charging technique
US5944012A (en) * 1996-03-25 1999-08-31 Pera; Ivo E. Method for dispensing antioxidant vitamins by inhalation background of the invention
ATE247948T1 (en) * 1996-04-29 2003-09-15 Dura Pharma Inc METHOD FOR INHALING DRY POWDER
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5871010A (en) 1996-06-10 1999-02-16 Sarnoff Corporation Inhaler apparatus with modified surfaces for enhanced release of dry powders
US5857456A (en) * 1996-06-10 1999-01-12 Sarnoff Corporation Inhaler apparatus with an electronic means for enhanced release of dry powders
US6192882B1 (en) * 1997-02-24 2001-02-27 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US6349719B2 (en) 1997-02-24 2002-02-26 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
ATE238773T1 (en) * 1997-08-26 2003-05-15 Aventis Pharma Inc MEDICINAL PRODUCTS FOR THE COMBINATION OF PIPERIDINOALKANOL-DECONGESTIVE
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6352722B1 (en) 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
US7963955B2 (en) * 1998-02-27 2011-06-21 Boehringer Ingelheim International Gmbh Container for a medicinal liquid
US6149774A (en) 1998-06-10 2000-11-21 Delsys Pharmaceutical Corporation AC waveforms biasing for bead manipulating chucks
US6234167B1 (en) 1998-10-14 2001-05-22 Chrysalis Technologies, Incorporated Aerosol generator and methods of making and using an aerosol generator
DZ2947A1 (en) * 1998-11-25 2004-03-15 Chiesi Farma Spa Pressure metered dose inhaler.
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
IT1313553B1 (en) 1999-07-23 2002-09-09 Chiesi Farma Spa OPTIMIZED FORMULATIONS CONSTITUTED BY SOLUTIONS OF STEROIDS GIVEN BY INHALATION.
IT1317720B1 (en) * 2000-01-07 2003-07-15 Chiesi Farma Spa DEVICE FOR THE ADMINISTRATION OF AEROSOL DOSED PRESSURIZED INPROPELLENT HYDROFLUOROALKANS.
IT1317846B1 (en) 2000-02-22 2003-07-15 Chiesi Farma Spa FORMULATIONS CONTAINING AN ANTICOLINERGIC DRUG FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE BRONCOPNEUMOPATHY.
AU3400501A (en) 2000-02-28 2001-09-12 Vectura Ltd Improvements in or relating to the delivery of oral drugs
US6369115B1 (en) 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
AU2001252350A1 (en) * 2000-04-13 2001-10-30 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
PT1280520E (en) 2000-05-10 2014-12-16 Novartis Ag Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
IT1318514B1 (en) * 2000-05-12 2003-08-27 Chiesi Farma Spa FORMULATIONS CONTAINING A GLUCOCORTICOSTEROID DRUG FOR THE TREATMENT OF BRONCOPOLMONARY DISEASES.
CZ303833B6 (en) * 2000-05-22 2013-05-22 Chiesi Farmaceutici S.P.A. Aerosol composition
AU2001260611A1 (en) * 2000-05-26 2001-12-03 Takeda Chemical Industries Ltd. Drugs acting on the bronchi
ES2708961T3 (en) 2000-11-30 2019-04-12 Vectura Ltd Pharmaceutical compositions for inhalation
US6799572B2 (en) 2000-12-22 2004-10-05 Chrysalis Technologies Incorporated Disposable aerosol generator system and methods for administering the aerosol
US6501052B2 (en) 2000-12-22 2002-12-31 Chrysalis Technologies Incorporated Aerosol generator having multiple heating zones and methods of use thereof
US6681998B2 (en) 2000-12-22 2004-01-27 Chrysalis Technologies Incorporated Aerosol generator having inductive heater and method of use thereof
US6701921B2 (en) 2000-12-22 2004-03-09 Chrysalis Technologies Incorporated Aerosol generator having heater in multilayered composite and method of use thereof
US6491233B2 (en) 2000-12-22 2002-12-10 Chrysalis Technologies Incorporated Vapor driven aerosol generator and method of use thereof
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
US6482429B1 (en) * 2001-06-20 2002-11-19 Boehringer Ingelheim Pharmaceuticals, Inc. Stable powder inhalation dosage formulation
TR200401980T4 (en) * 2001-07-02 2004-09-21 Chiesi Farmaceutici S.P.A. Tobramycin formulation optimized for aerosol administration
US6640050B2 (en) 2001-09-21 2003-10-28 Chrysalis Technologies Incorporated Fluid vaporizing device having controlled temperature profile heater/capillary tube
US6568390B2 (en) 2001-09-21 2003-05-27 Chrysalis Technologies Incorporated Dual capillary fluid vaporizing device
US7931022B2 (en) * 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
US6804458B2 (en) 2001-12-06 2004-10-12 Chrysalis Technologies Incorporated Aerosol generator having heater arranged to vaporize fluid in fluid passage between bonded layers of laminate
US6681769B2 (en) 2001-12-06 2004-01-27 Crysalis Technologies Incorporated Aerosol generator having a multiple path heater arrangement and method of use thereof
SI1458360T1 (en) 2001-12-19 2011-08-31 Novartis Ag Pulmonary delivery of aminoglycosides
US6701922B2 (en) 2001-12-20 2004-03-09 Chrysalis Technologies Incorporated Mouthpiece entrainment airflow control for aerosol generators
ES2779273T3 (en) * 2002-03-01 2020-08-14 Chiesi Farm Spa Superfine Formoterol Formulation
US6705316B2 (en) 2002-03-11 2004-03-16 Battelle Pulmonary Therapeutics, Inc. Pulmonary dosing system and method
CA2479751C (en) 2002-03-20 2008-06-03 Trent Poole Inhalation apparatus
US20030200115A1 (en) * 2002-04-23 2003-10-23 Arun Arora Method for reporting medical data
LT1531794T (en) * 2002-06-28 2017-08-25 Civitas Therapeutics, Inc. Inhalable epinephrine
ATE432697T1 (en) 2002-11-18 2009-06-15 Yaupon Therapeutics Inc ANALGESIC USE OF (S)-NORKETAMIN
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
ES2385934T3 (en) 2004-08-20 2012-08-03 Mannkind Corporation CATALYSIS OF THE SYNTHESIS OF DICETOPIPERAZINA.
KR101644250B1 (en) 2004-08-23 2016-07-29 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
DK1928423T3 (en) 2005-09-14 2016-02-29 Mannkind Corp A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
US7566743B2 (en) * 2005-11-18 2009-07-28 Mark Glazman System and method for medical treatment
US8039431B2 (en) 2006-02-22 2011-10-18 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
AU2009257311B2 (en) 2008-06-13 2014-12-04 Mannkind Corporation A dry powder inhaler and system for drug delivery
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
AU2009276498A1 (en) * 2008-07-30 2010-02-04 Stc.Unm Formulations containing large-size carrier particles for dry powder inhalation aerosols
TWI532497B (en) 2008-08-11 2016-05-11 曼凱公司 Use of ultrarapid acting insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2400950B1 (en) 2009-02-26 2019-05-22 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
JP5667095B2 (en) 2009-03-11 2015-02-12 マンカインド コーポレイション Apparatus, system and method for measuring inhaler resistance
CA2764505C (en) 2009-06-12 2018-09-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
RU2571331C1 (en) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Systems and methods for dry powder drug delivery
US20120183949A1 (en) * 2011-01-19 2012-07-19 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, or system using lung sensor for detecting a physiological condition in a vertebrate subject
CN105667994B (en) 2011-04-01 2018-04-06 曼金德公司 Blister package for pharmaceutical kit
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
ES2754388T3 (en) 2013-03-15 2020-04-17 Mannkind Corp Compositions and methods of microcrystalline dicetopiperazine
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4143658A (en) * 1975-07-21 1979-03-13 Minnesota Mining And Manufacturing Company Intratracheal injection system for animals
DE3274065D1 (en) * 1981-07-08 1986-12-11 Draco Ab POWDER INHALATOR
SE438261B (en) * 1981-07-08 1985-04-15 Draco Ab USE IN A DOSHALATOR OF A PERFORED MEMBRANE
CA1224992A (en) * 1982-10-08 1987-08-04 Robert E. Newell Device for administering medicament to patients
EP0110498B2 (en) * 1982-11-22 1991-09-18 Teijin Limited Artificial lung surfactant and remedy for respiratory distress syndrome containing it as active principle
US4570630A (en) * 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
SE448277B (en) * 1985-04-12 1987-02-09 Draco Ab INDICATOR DEVICE WITH A DOSAGE DEVICE FOR MEDICINAL PRODUCTS
SE453566B (en) * 1986-03-07 1988-02-15 Draco Ab POWDER INHALATOR DEVICE
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
GB8909891D0 (en) * 1989-04-28 1989-06-14 Riker Laboratories Inc Device
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
US5192548A (en) * 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
SE9002895D0 (en) * 1990-09-12 1990-09-12 Astra Ab INHALATION DEVICES FOR DISPENSING POWDERS I
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5327883A (en) * 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US5161524A (en) * 1991-08-02 1992-11-10 Glaxo Inc. Dosage inhalator with air flow velocity regulating means
US6119688A (en) * 1991-08-26 2000-09-19 3M Innovative Properties Company Powder dispenser
EP0530440A1 (en) * 1991-09-02 1993-03-10 International Software Corp. Copper oxide whiskers and process for producing the same
DE4140689B4 (en) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalable powders and process for their preparation
EP0558879B1 (en) * 1992-03-04 1997-05-14 Astra Aktiebolag Disposable inhaler
SE9203743D0 (en) * 1992-12-11 1992-12-11 Astra Ab EFFICIENT USE
US5349947A (en) * 1993-07-15 1994-09-27 Newhouse Michael T Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow

Also Published As

Publication number Publication date
IS4102A (en) 1994-06-12
CA2148617A1 (en) 1994-06-23
AU5663494A (en) 1994-07-04
JPH08504438A (en) 1996-05-14
WO1994013271A1 (en) 1994-06-23
US6360743B1 (en) 2002-03-26
EP0673244A1 (en) 1995-09-27
US5642728A (en) 1997-07-01
SE9203743D0 (en) 1992-12-11
US5934273A (en) 1999-08-10

Similar Documents

Publication Publication Date Title
CA2148617C (en) System for dispensing pharmaceutically active compounds
US6250300B1 (en) System for dispensing pharmaceutically active compounds
US11213485B2 (en) Pharmaceutical solution formulations for pressurized metered dose inhalers
US6475523B1 (en) Powders comprising anti-adherant materials for use in dry powder inhalers
US20070110678A1 (en) Method for administration of tiotropium
JP2013075909A (en) Aerosol composition comprising formoterol
EP0750492A1 (en) Inhalation composition containing lactose pellets
US20030186843A1 (en) Powders for use in a dry powder inhaler
US20080107740A1 (en) Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders
Pauwels et al. Influence of an extension tube on the bronchodilator efficacy of terbutaline delivered from a metered dose inhaler
COL et al. Salbutamol powder, administered via a multidose and a single-dose powder inhaler, in the prevention of exercise-induced asthma in children
CA2540005A1 (en) Pulmonary disease treatment
WO2022146254A1 (en) A process for the preparation of dry powder compositions for inhalation
Newman et al. Lung deposition of pressurised terbutaline sulphate aerosols compared by two techniques
WO2023128916A1 (en) An apparatus with a grid (10) for the preparation of dry powder compositions for inhalation
WO2022045993A1 (en) A production method of dry powder compositions for inhalation
WO2022045995A1 (en) A process for the preparation of dry powder compositions for inhalation
CN114514020A (en) Novel carrier particles for dry powder formulations for inhalation
Raval et al. In Vitro Aerosol Measurements of the Novel Single Dose Reusable Dry Power Inhaler with Combination of Long-Acting Bronchodilator and Inhalated Corticosteroid

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20131209